ערך בספרים למניה: Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals (OLMA) is implementing robotic compound screening and clinical analysis software, expanding its oncology market reach by developing innovative oral SERDs for ER-positive patients. The company's market valuation trend currently stands at 4.97. The business is building a comprehensive women's health ecosystem by merging fundamental hormone science with the production of targeted therapies, setting new standards in tumor treatment.

Fundamental analysis of this asset requires strict capital preservation to minimize investment risks. This is critical for Olema Pharmaceuticals (OLMA), as the absence of revenue coupled with costly oncology trials leads to a rapid burn rate of reserves. The historical book value per share reflects the remaining equity divided by the number of shares outstanding. The downward trend on this chart signals losses and write-downs. This metric determines the actual tangible value of a single investor's holding.